콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

SML3976

Sigma-Aldrich

Apremilast

≥98% (HPLC)

동의어(들):

(S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulphonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide, CC 10004, CC-10004, CC10004, N-[2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C22H24N2O7S
CAS Number:
Molecular Weight:
460.50
MDL number:
UNSPSC 코드:
12352200

Quality Level

분석

≥98% (HPLC)

양식

powder

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

저장 온도

-10 to -25°C

SMILES string

[S](=O)(=O)(C[C@@H](N2C(=O)c3c(cccc3NC(=O)C)C2=O)c1cc(c(cc1)OC)OCC)C

InChI

1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1

InChI key

IMOZEMNVLZVGJZ-QGZVFWFLSA-N

생화학적/생리학적 작용

Orally active, potent and selective phosphodiesterase 4 (PDE4) inhibitor in vitro and in vivo.



Apremilast (CC-10004) is an orally active, potent and selective phosphodiesterase 4 (PDE4) inhibitor (IC50 = 20/49/50/30 nM with recombinant human PDE4A4/B2/C2/D3 and 1 μM cAMP; no significant PDE1/2/3/5/7/8/9/10/11 inhibition at 10 μM). Apremilast effectively inhibits LPS-induced cytokine and chemokine protein expression from purified human PBMCs (TNFα/IFNγ/IL12 IC50 = 13/110/120 nM, IP10/MIG/MIP1α IC50 = 10/28/40 nM) in vitro and exhibits therapeutic efficacy in a psoriasis mouse model in vivo (2.5/mg/kg b.i.d. p.o.)

픽토그램

Health hazardExclamation mark

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2 - STOT SE 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Fiona E McCann et al.
Arthritis research & therapy, 12(3), R107-R107 (2010-06-08)
Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target
P H Schafer et al.
British journal of pharmacology, 159(4), 842-855 (2010-01-07)
Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other chronic inflammatory diseases. The inhibitory effects of apremilast on pro-inflammatory responses of human primary peripheral blood mononuclear cells (PBMC), polymorphonuclear cells, natural killer
Hon-Wah Man et al.
Journal of medicinal chemistry, 52(6), 1522-1524 (2009-03-05)
In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha inhibitor. The optimization of previously reported 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionic acid PDE4 inhibitors led to this series of sulfone analogues.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.